caa a22 4500 397591934 CHVBK 20180308164941.0 cr unu---uuuuu 161202e199608 xx s 000 0 eng 10.1093/jac/38.2.293 doi (NATIONALLICENCE)oxford-10.1093/jac/38.2.293 Effect of replacing cefotaxime with ceftizoxime in a hospital where penicillin-resistant pneumococcal disease is prevalent [Elektronische Daten] [David W. Haas, Thad Bonczar] Ceftizoxime and cefotaxime demonstrate very similar activities in vitro against a broad range of bacteria. To reduce costs, our hospital pharmacy implemented an automatic substitution policy whereby ceftizoxime was dispensed and administered whenever cefotaxime was ordered. This policy was modified when penicillin-resistant Streptococcus pneumoniac isolates were found to be markedly less susceptible to ceftizoxime than to cefotaxime, of concern considering the prevalence and virulence of this pathogen. We compared clinical findings among 179 adult patients treated with ceftizoxime for any indication during the substitution months with 200 patients treated with cefotaxime during the previous year. The ceftizoxime group had a shorter mean length of stay, which paralleled a hospital-wide trend toward more efficient discharge planning. After adjusting for this trend, we observed no significant difference in duration of study drug, number of other intravenous antibiotics, likelihood of receiving additional antibiotics after study drug completion, or patient survival. Fortuitously, no penicillin-resistant pneumocoaral infections were documented in ceftizoxime-treated patients. This study suggests that cefotaxime and ceftizoxime are commrable. The choice of one versus the other mav be dictated by price, provided ceftizoxime is not used for proven or suspected penicillin-resistani pneumococcal infections. © 1996 by the British Society for Antimicrobial Chemotherapy Antimicrobial practice nationallicence Haas David W. Departments of Medicine, Microbiology and Immunology, Division of Inferctious Diseases 911 Oxford House Nashville, Tennessee 37232-4751, USA aut Bonczar Thad Pharmacy Services, Vanderbilt University School of Medicine 911 Oxford House Nashville, Tennessee 37232-4751, USA aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/2(1996-08), 293-299 0305-7453 38:2<293 1996 38 jac https://doi.org/10.1093/jac/38.2.293 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.2.293 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Haas David W. Departments of Medicine, Microbiology and Immunology, Division of Inferctious Diseases 911 Oxford House Nashville, Tennessee 37232-4751, USA aut NATIONALLICENCE 700 1- Bonczar Thad Pharmacy Services, Vanderbilt University School of Medicine 911 Oxford House Nashville, Tennessee 37232-4751, USA aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/2(1996-08), 293-299 0305-7453 38:2<293 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford